Selected Publications:
Karasic TB, O’Hara MH, Loaiza-Bonilla A, Reiss-Binder KA, Teitelbaum UR, Borazanci E, De Jesus-Acosta AC, Redlinger C, Burrell JA, Laheru DA, Von Hoff DD, Amaravadi RK, Drebin JA, O’Dwyer PJ.: Randomized phase II trial of hydroxychloroquine in combination with gemcitabine/nab-paclitaxel to inhibit autophagy in pancreatic cancer: A SU2C-funded trial. American Association for Cancer Research Annual Meeting, Chicago, IL : 2018.
Karasic TB1, Rosen MA2, O'Dwyer PJ3.: Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective? Cancer Chemother Pharmacol. 80 (4): 661-671,2017.
Karasic TB, Rosen MA, O’Dwyer PJ.: Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective? Cancer Chemother Pharmacol. : 2017.
O'Hara MH, Karasic TB, Vasilevskaya I, Redlinger M, Loaiza-Bonilla A, Teitelbaum UR, Giantonio BJ, Damjanov N, Reiss KA, Rosen MA, Heitjan DF, Troxel AB, Amaravadi RK, O'Dwyer PJ.: Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting, Chicago, IL : 2017.
Karasic TB, O’Hara MH, Teitelbaum UR, Damjanov N, Giantonio BJ, D’Entremont TS, Gallagher M, Zhang P, O’Dwyer PJ.: Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer. American Society of Clinical Oncology Annual Meeting, Chicago, IL : 2017.
Karasic T, Loaiza-Bonilla A.: Immunotherapy for hepatobiliary malignancies. GI ASCO 2017 Daily News. : 2017.
Clark AS, Karasic TB, DeMichele A, Vaughn DJ, O'Hara M, Perini R, Zhang P, Lal P, Feldman M, Gallagher M, O'Dwyer PJ. Palbociclib: (PD0332991) - a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development. JAMA Oncol. 2 (2): 253-60,2016 .
Clark AS, Karasic TB, DeMichele A, Vaughn DJ, O'Hara M, Perini R, Zhang P, Lal P, Feldman M, Gallagher M, O'Dwyer PJ.: Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development. JAMA Oncol. 2 (2): 253-60,2016.
Karasic TB, Hei TK, Ivanov VN: Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. Exp Cell Res 316 (12): 1994-2007,2010.
Ivanov VN, Zhou H, Ghandhi SA, Karasic TB, Yaghoubian B, Amundson SA, Hei TK.: Radiation-induced bystander signaling pathways in human fibroblasts: a role for interleukin-33 in the signal transmission. Cell Signal 22 (7): 1076-87,2010.